GOBLET Group 4 trial of pelareorep with atezolizumab fails to reach median overall survival

Oncolytics Biotech announced that Group 4 of its Phase 1/2 GOBLET trial of pelareorep in combination with atezolizumab failed to reach median overall survival.

Detected & updated continuously · Source: Nebula